Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest Jumps Back Into Diabetes In Deal With TransTech For Glucokinase Activators

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest agreed to pay $50 million upfront for rights to several compounds in a novel class of drugs, including a lead drug that is Phase II-ready.

You may also be interested in...



Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put Lexapro Behind It?

Forest Laboratories, Inc. has late-stage products lined up in its pipeline to help fill the gap left when Lexapro and Namenda go generic, but the burden on a specialty pharma to differentiate its products is a heavy one these days, and it will be a struggle to the finish to convince investors the cup is half full.

Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put Lexapro Behind It?

Forest Laboratories, Inc. has late-stage products lined up in its pipeline to help fill the gap left when Lexapro and Namenda go generic, but the burden on a specialty pharma to differentiate its products is a heavy one these days, and it will be a struggle to the finish to convince investors the cup is half full.

Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes

DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel